Literature DB >> 26707918

Ulipristal Acetate Before High Complexity Hysteroscopic Myomectomy: A Retrospective Comparative Study.

Simone Ferrero1, Annalisa Racca2, Emanuela Tafi2, Franco Alessandri3, Pier Luigi Venturini2, Umberto Leone Roberti Maggiore2.   

Abstract

STUDY
OBJECTIVE: To evaluate the efficacy of preoperative treatment with ulipristal acetate (UPA) in patients undergoing high complexity hysteroscopic myomectomy.
DESIGN: Retrospective analysis of a prospectively collected database (Canadian Task Force classification II-2).
SETTING: University teaching hospital. PATIENTS: Patients of reproductive age requiring hysteroscopic myomectomy with STEPW (size, topography, extension, penetration, and wall) score 5 or 6.
INTERVENTIONS: Patients included in the study either underwent direct surgery (group S) or received a 3-month preoperative treatment with UPA (group UPA). Based on a power calculation, 25 patients were required in each study group.
MEASUREMENTS AND MAIN RESULTS: Myoma characteristics were similar in the 2 study groups. The 3-month UPA treatment caused a 21.9% (±10.3%) mean (±SD) percentage decrease in myoma volume. The number of complete resections (primary outcome of the study) was higher in group UPA (92.0%) than in group S (68.0%; p = .034). The operative time was lower in group UPA than in group S (p = .048), whereas there was no significant difference in fluid balance between the 2 study groups (p = .256). The incidence of complications was similar in the 2 groups (p = .609). Patient satisfaction at 3 months from surgery was higher in group UPA than in group S (p = .041).
CONCLUSION: A 3-month preoperative treatment with UPA increases the possibility of complete resection in high complexity hysteroscopic myomectomy. It decreases the operative time and improves patient satisfaction at 3 months from surgery.
Copyright © 2016 AAGL. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hysteroscopy; Myomectomy; Resection; Ulipristal acetate; Uterine myoma

Mesh:

Substances:

Year:  2015        PMID: 26707918     DOI: 10.1016/j.jmig.2015.12.002

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  7 in total

1.  What happens after randomised controlled trials? Uterine fibroids and ulipristal acetate: systematic review and meta-analysis of "real-world" data.

Authors:  Neha Shah; Elizabeth Egbase; Michael Sideris; Funlayo Odejinmi
Journal:  Arch Gynecol Obstet       Date:  2021-01-02       Impact factor: 2.344

Review 2.  Ulipristal acetate before high complexity endoscopic (hysteroscopic, laparoscopic) myomectomy - a mini-review.

Authors:  Włodzimierz Baranowski
Journal:  Prz Menopauzalny       Date:  2017-02-08

3.  The Use of Ulipristal Acetate (Esmya) Prior to Laparoscopic Myomectomy: Help or Hindrance?

Authors:  Rebecca Mallick; Sam Oxley; Funlayo Odejinmi
Journal:  Gynecol Minim Invasive Ther       Date:  2019-04-29

4.  Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids.

Authors:  Giuseppe Morgante; Gabriele Centini; Libera Troìa; Raoul Orvieto; Vincenzo De Leo
Journal:  Reprod Biol Endocrinol       Date:  2020-05-19       Impact factor: 5.211

5.  Operative hysteroscopy platform at a university teaching hospital: a retrospective study.

Authors:  Naser Al-Husban; Rana Abu Rokbeh
Journal:  J Int Med Res       Date:  2019-07-29       Impact factor: 1.671

Review 6.  Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids.

Authors:  Mohamed Ali; Ayman Al-Hendy
Journal:  Biol Reprod       Date:  2017-09-01       Impact factor: 4.285

Review 7.  Is ulipristal acetate the new drug of choice for the medical management of uterine fibroids? Res ipsa loquitur?

Authors:  Funlayo Odejinmi; Reeba Oliver; Rebecca Mallick
Journal:  Womens Health (Lond)       Date:  2017-11-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.